What is JMD Properties Inc?
, a research diagnostics company, engages in developing molecular diagnostics tools and new drug targets for esophageal diseases.
SLDX · Verdict
Limited reward · elevated risk
SLDX's standout is volatility; cash flow and profitability weigh on the picture.
Based on 88% data coverage
SLDX · Verdict
Top decile vs peers
Weak vs peers
0% return on equity
Earnings -58.0% CAGR
Current ratio 0.00
Model-based scoring. For information only — not financial advice.
, a research diagnostics company, engages in developing molecular diagnostics tools and new drug targets for esophageal diseases. It uses targeted mass spectrometry to determine the level of disease progression in tissue of the lower esophagus. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.85M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.